Albireo to Participate in Upcoming Investor Conferences

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced participation in upcoming investor conferences:

  • Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2022
    Simon Harford, Chief Financial Officer, and Colleen Alabiso, SVP, Corporate Affairs, will host meetings with investors.
  • Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022
    Ron Cooper, President and Chief Executive Officer, will be participating in a fireside chat from 10:30 – 11:00 am ET. Ron Cooper and Simon Harford will host meetings with investors.
  • H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022
    Pamela Stephenson, Chief Commercial Officer, will participate in a fireside chat available on September 12 at 7:00 am ET. Pamela Stephenson and Christine Clemson, SVP, Head of Global Medical Affairs, will conduct investor meetings on September 12.
  • Baird 2022 Global Healthcare Conference on Tuesday, September 13, 2022
    Ron Cooper will be presenting from 8:30 – 9:00 am ET. Ron Cooper and Simon Harford will host meetings with investors.

A replay of all webcasts will be available on-demand on the Albireo Investors page ir.albireopharma.com.

About Albireo

Albireo Pharma is a rare disease company focused on the development of novel bile acid modulators to treat pediatric and adult liver diseases. Albireo’s lead product, Bylvay, was approved by the U.S. FDA as the first drug for the treatment of pruritus in all types of progressive familial intrahepatic cholestasis (PFIC), and in Europe, Bylvay has been approved for the treatment of PFIC. Bylvay is also being developed to treat other rare pediatric cholestatic liver diseases with global Phase 3 trials in Alagille syndrome (ALGS) and biliary atresia, as well as Open-label Extension (OLE) studies for PFIC and ALGS. The Company has also completed a Phase 1 clinical trial for A3907 to advance development in adult cholestatic liver disease, with IND-enabling studies progressing with A2342 for viral and cholestatic liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.

Media Contacts:
Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com
Lance Buckley, 917-439-2241, lbuckley@lippetaylor.com

Investor Contact:
Hans Vitzthum, LifeSci Advisors, LLC., 617-430-7578

Staff

Recent Posts

Masimo Provides Facts in Response to Politan’s False Narrative

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today issued the following statement to set the record straight…

1 hour ago

CAREIUM & CSL EXTEND THEIR PARTNERSHIP WITH THE LAUNCH OF rSIM® TECHNOLOGY

Innovation Leaders in Technology-Enabled Care, Careium, and Critical Connectivity Experts, CSL, have announced the extension…

1 hour ago

Dagfinn Hallseth of NEO Consulting Receives Prestigious Recognition in 2024 Business Worldwide Magazine CEO Awards

Dagfinn Hallseth, CEO and founder of NEO Consulting AS, has been awarded the title of…

1 hour ago

Independent Cradle-to-Gate life cycle assessment shows AMSilk’s fibers have a significantly lower environmental footprint compared to silk

NEURIED, Germany, June 20, 2024 /PRNewswire/ -- AMSilk GmbH ("AMSilk"), a frontrunner in advanced biomaterials…

1 hour ago

Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

Drs. Marko Radic and Georg Schett Honored at FOCIS 2024 Meeting SAN FRANCISCO, June 20,…

1 hour ago

Ping An Receives Five “All-Asia Executive Team 2024” Accolades From Institutional Investor Magazine

HONG KONG and SHANGHAI, June 20, 2024 /PRNewswire/ -- Institutional Investor magazine has announced the…

1 hour ago